Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Integer announces opening of The Galway R&D Innovation Centre » 16:07
06/25/20
06/25
16:07
06/25/20
16:07
ITGR

Integer

$68.33 /

-2.21 (-3.13%)

Integer Holdings…

Integer Holdings announced the opening of The Galway Research and Development, R&D, Innovation Centre in Ireland. The new facility will further enhance Integer's capability to provide high-quality medical devices and technologies that help sustain and save the lives of patients worldwide. The Galway R&D Innovation Centre will enable Integer to provide a collaborative environment where both Integer and our customers' teams can work together to ideate and develop new and innovative devices. "Integer continues to make key investments to help support our customers' innovation and growth," said Payman Khales, president of Integer's cardio and vascular business. "The Galway R&D Innovation Centre will allow us to enhance our current capabilities, while accelerating the development of a broad range of cardio and vascular products." Located in Claregalway, six kilometers from Integer's main Galway, Ireland, facility, the new, fully dedicated 8,500 square foot facility will support Integer's customers across the globe, including the significant medical device cluster in Ireland. The facility features a versatile workspace for the R&D team to collaborate with customers on innovative technical solutions that meet their evolving needs. There is also a significant increase in development lab space, providing the team room to grow and add capabilities, including space for a cleanroom pilot line. In addition, the opening of this new dedicated facility, frees up space allowing the Galway manufacturing site to expand, increase capacity and add new equipment as required to meet customers' needs.

ShowHide Related Items >><<
ITGR Integer
$68.33 /

-2.21 (-3.13%)

ITGR Integer
$68.33 /

-2.21 (-3.13%)

05/14/20 Benchmark
Benchmark starts Integer at Buy after 'strong' Q1 report
05/14/20 Benchmark
Integer initiated with a Buy at Benchmark
ITGR Integer
$68.33 /

-2.21 (-3.13%)

Conference/Events
Integer management to meet virtually with KeyBanc » 04:55
06/24/20
06/24
04:55
06/24/20
04:55
ITGR

Integer

$76.22 /

+2.59 (+3.52%)

Virtual Meeting to be…

Virtual Meeting to be held on June 24 hosted by KeyBanc.

ShowHide Related Items >><<
ITGR Integer
$76.22 /

+2.59 (+3.52%)

ITGR Integer
$76.22 /

+2.59 (+3.52%)

05/14/20 Benchmark
Benchmark starts Integer at Buy after 'strong' Q1 report
05/14/20 Benchmark
Integer initiated with a Buy at Benchmark
ITGR Integer
$76.22 /

+2.59 (+3.52%)

Conference/Events
Integer management to meet virtually with KeyBanc » 12:14
06/22/20
06/22
12:14
06/22/20
12:14
ITGR

Integer

$72.80 /

-1.98 (-2.65%)

Virtual Meeting to be…

Virtual Meeting to be held on June 24 hosted by KeyBanc.

ShowHide Related Items >><<
ITGR Integer
$72.80 /

-1.98 (-2.65%)

ITGR Integer
$72.80 /

-1.98 (-2.65%)

05/14/20 Benchmark
Benchmark starts Integer at Buy after 'strong' Q1 report
05/14/20 Benchmark
Integer initiated with a Buy at Benchmark
ITGR Integer
$72.80 /

-1.98 (-2.65%)

Over a month ago
Initiation
Benchmark starts Integer at Buy after 'strong' Q1 report » 07:35
05/14/20
05/14
07:35
05/14/20
07:35
ITGR

Integer

$70.71 /

-3.1 (-4.20%)

As previously reported,…

As previously reported, Benchmark analyst Robert Wasserman initiated coverage of Integer with a Buy rating and $105 price target. Integer is one of the world's largest medical device outsource manufacturers and its "strong" Q1 results and leading market position highlight its value, Wasserman tells investors.

ShowHide Related Items >><<
ITGR Integer
$70.71 /

-3.1 (-4.20%)

ITGR Integer
$70.71 /

-3.1 (-4.20%)

05/14/20 Benchmark
Integer initiated with a Buy at Benchmark
06/05/19 Argus
Integer price target lowered to $90 from $103 at Argus
ITGR Integer
$70.71 /

-3.1 (-4.20%)

Initiation
Integer initiated with a Buy at Benchmark » 06:32
05/14/20
05/14
06:32
05/14/20
06:32
ITGR

Integer

$70.71 /

-3.1 (-4.20%)

Benchmark analyst Robert…

Benchmark analyst Robert Wasserman initiated coverage of Integer with a Buy rating and $105 price target.

ShowHide Related Items >><<
ITGR Integer
$70.71 /

-3.1 (-4.20%)

ITGR Integer
$70.71 /

-3.1 (-4.20%)

06/05/19 Argus
Integer price target lowered to $90 from $103 at Argus
ITGR Integer
$70.71 /

-3.1 (-4.20%)

Over a quarter ago
Conference/Events
Barclays to hold a conference » 04:55
03/12/20
03/12
04:55
03/12/20
04:55
ABC

AmerisourceBergen

$84.90 /

-1.21 (-1.41%)

, AMAG

Amag Pharmaceuticals

$6.62 /

-0.64 (-8.82%)

, AZN

AstraZeneca

$44.57 /

-2.32 (-4.95%)

, AVNS

Avanos

$29.00 /

-3.11 (-9.69%)

, BDX

Becton Dickinson

$232.14 /

-5.18 (-2.18%)

, BIO

Bio-Rad

$345.64 /

-21.41 (-5.83%)

, CAH

Cardinal Health

$48.77 /

-0.94 (-1.89%)

, CLVS

Clovis

$6.16 /

-0.105 (-1.68%)

, COO

Cooper Companies

$323.96 /

-10.03 (-3.00%)

, CVS

CVS Health

$61.26 /

-1.36 (-2.17%)

, DGX

Quest Diagnostics

$99.75 /

-6.65 (-6.25%)

, EHTH

eHealth

$126.95 /

-6.99 (-5.22%)

, EXEL

Exelixis

$17.32 /

-1.09 (-5.92%)

, FATE

Fate Therapeutics

$23.79 /

-2.2 (-8.46%)

, FLDM

Fluidigm

$2.62 /

-0.27 (-9.34%)

, FMS

Fresenius Medical

$35.40 /

-2.24 (-5.95%)

, GRTS

Gritstone Oncology

$6.64 /

-0.39 (-5.55%)

, HRC

Hill-Rom

$89.24 /

-0.89 (-0.99%)

, HUM

Humana

$328.50 /

-20.52 (-5.88%)

, IMMU

Immunomedics

$13.38 /

-1.9 (-12.43%)

, IRWD

Ironwood

$10.49 /

-0.96 (-8.38%)

, ITGR

Integer

$79.28 /

-4.07 (-4.88%)

, JAZZ

Jazz Pharmaceuticals

$108.33 /

-4.42 (-3.92%)

, JNJ

Johnson & Johnson

$131.65 /

-10.05 (-7.09%)

, ZIOP

Ziopharm

$2.53 /

-0.24 (-8.68%)

, VNDA

Vanda Pharmaceuticals

$10.60 /

-0.2 (-1.85%)

, QGEN

Qiagen

$41.10 /

-0.33 (-0.80%)

, MRNA

Moderna

$23.61 /

+1.27 (+5.68%)

, MTD

Mettler-Toledo

$661.68 /

-35 (-5.02%)

, MTEM

Molecular Templates

$13.20 /

-1.48 (-10.08%)

, NTRA

Natera

$31.00 /

+0.07 (+0.23%)

, PODD

Insulet

$172.13 /

-8.29 (-4.59%)

, PTCT

PTC Therapeutics

$47.07 /

-4.23 (-8.25%)

Global Healthcare…

Global Healthcare Conference 2020 will be held in Miami on March 10-12.

ShowHide Related Items >><<
ABC AmerisourceBergen
$84.90 /

-1.21 (-1.41%)

02/07/20 Baird
AmerisourceBergen upgraded to Outperform at Baird
02/07/20 Baird
AmerisourceBergen upgraded to Outperform from Neutral at Baird
01/28/20 Cleveland Research
AmerisourceBergen appears to be gaining share, says Cleveland Research
10/16/19 Jefferies
Drug distributor settlement would make stocks 'ownable again,' says Jefferies
AMAG Amag Pharmaceuticals
$6.62 /

-0.64 (-8.82%)

03/04/20 Piper Sandler
Amag Pharmaceuticals price target lowered to $7 from $9 at Piper Sandler
03/03/20 H.C. Wainwright
Amag Pharmaceuticals price target lowered to $12 from $16 at H.C. Wainwright
01/09/20 Piper Sandler
Amag business still facing 'significant challenges,' says Piper Sandler
11/04/19 Barclays
Amag Pharmaceuticals price target lowered to $14 from $16 at Barclays
AZN AstraZeneca
$44.57 /

-2.32 (-4.95%)

02/28/20 Cowen
AstaZeneca pipeline leads to best European idea, says Cowen
01/27/20 William Blair
PhaseBio could see increase to PB2452 addressable market, says William Blair
01/22/20 Liberum
Sanofi downgraded to Hold from Buy at Liberum (earlier)
01/22/20 Oppenheimer
Amarin price target raised to $13 from $8 at Oppenheimer
AVNS Avanos
$29.00 /

-3.11 (-9.69%)

12/30/19 Stifel
Avanos makes 'welcome addition' with 'highly experienced' CFO, says Stifel
11/06/19 Stifel
Avanos downgraded to Hold from Buy at Stifel
11/06/19 Stifel
Avanos downgraded to Hold from Buy at Stifel
11/06/19 Raymond James
Avanos shares could be range-bound over next six months, says Raymond James
BDX Becton Dickinson
$232.14 /

-5.18 (-2.18%)

03/04/20 Citi
Becton Dickinson initiated with a Neutral at Citi
03/02/20 Wells Fargo
Baxter, J&J best positioned to weather coronavirus spread, says Wells Fargo
02/07/20
Fly Intel: Top five analyst downgrades
02/07/20 Raymond James
Becton Dickinson downgraded at Raymond James given pump overhang
BIO Bio-Rad
$345.64 /

-21.41 (-5.83%)

03/03/20 Citi
Bio-Rad margin expansion story in early innings, says Citi
01/07/20 Wells Fargo
Wells Fargo initiates Life Science Tools, Services, Diagnostics Sector
01/07/20 Wells Fargo
Bio-Rad initiated with an Overweight at Wells Fargo
01/06/20 Citi
Citi calls Bio-Rad, Thermo Fisher top picks in Tools industry
CAH Cardinal Health
$48.77 /

-0.94 (-1.89%)

02/12/20 Morgan Stanley
Cardinal Health upgraded to Equal Weight from Underweight at Morgan Stanley
02/07/20 Baird
Cardinal Health upgraded to Outperform at Baird
02/07/20 Mizuho
Cardinal Health price target raised to $58 from $52 at Mizuho
02/07/20 Baird
Cardinal Health upgraded to Outperform from Neutral at Baird
CLVS Clovis
$6.16 /

-0.105 (-1.68%)

02/25/20
Fly Intel: Top five analyst initiations
02/25/20 RBC Capital
Clovis initiated with an Outperform at RBC Capital
01/08/20 H.C. Wainwright
Clovis price target lowered to $27 from $36 at H.C. Wainwright
01/07/20 Piper Sandler
Clovis modestly extends cash runway with debt deal, says Piper Sandler
COO Cooper Companies
$323.96 /

-10.03 (-3.00%)

03/06/20 Baird
Cooper Companies price target raised to $357 from $345 at Baird
03/06/20 Piper Sandler
Cooper Companies price target raised to $351 from $344 at Piper Sandler
03/04/20 Citi
Cooper Companies initiated with a Neutral at Citi
CVS CVS Health
$61.26 /

-1.36 (-2.17%)

02/20/20 Stephens
Stephens watching near-term MCO stock reactions after Bloomberg's 'rough' debate
02/18/20 Deutsche Bank
Deutsche raises price targets in Managed Care on fading political risks
02/10/20 Cowen
CVS upside to guidance seen, says Cowen
01/21/20 Cantor Fitzgerald
CVS, Cigna and Centene a buy on any block grant selloff, says Cantor
DGX Quest Diagnostics
$99.75 /

-6.65 (-6.25%)

03/06/20 Jefferies
COVID-19 tests unlikely to move needle for Quest or LabCorp, says Jefferies
03/05/20 JPMorgan
Quest Diagnostics' COVID-19 testing to be small benefit for 2020, says JPMorgan
02/10/20 Mizuho
Quest Diagnostics price target raised to $122 from $116 at Mizuho
01/30/20 Piper Sandler
Quest Diagnostics price target raised to $107 from $102 at Piper Sandler
EHTH eHealth
$126.95 /

-6.99 (-5.22%)

02/24/20 Credit Suisse
eHealth price target raised to $179 from $145 at Credit Suisse
02/21/20 SunTrust
eHealth price target raised to $250 from $200 at SunTrust
02/21/20 Craig-Hallum
eHealth price target raised to $200 from $150 at Craig-Hallum
02/21/20 RBC Capital
eHealth price target raised to $166 from $132 at RBC Capital
EXEL Exelixis
$17.32 /

-1.09 (-5.92%)

03/04/20 Barclays
Barclays starts small, mid cap Biotechnology sector with Positive view
03/04/20 Barclays
Exelixis initiated with an Overweight at Barclays
02/27/20 Piper Sandler
Exelixis price target lowered to $23 from $35 at Piper Sandler
02/11/20 Piper Sandler
Exelixis data 'impressive,' support accelerated approval, says Piper Sandler
FATE Fate Therapeutics
$23.79 /

-2.2 (-8.46%)

03/04/20 Citi
Fate Therapeutics price target raised to $41 from $26 at Citi
03/04/20 Barclays
Fate Therapeutics initiated with an Overweight at Barclays
03/03/20 BMO Capital
Fate Therapeutics price target raised to $28 from $22 at BMO Capital
FLDM Fluidigm
$2.62 /

-0.27 (-9.34%)

02/11/20 Piper Sandler
Fluidigm price target lowered to $9 from $14 at Piper Sandler
01/14/20 Piper Sandler
Piper Sandler reiterates Overweight on Fluidigm after Q4 results, guidance
11/06/19 Janney Montgomery Scott
Fluidigm downgraded to Neutral after Q3 miss at Janney Montgomery Scott
11/06/19 Janney Montgomery Scott
Fluidigm downgraded to Neutral from Buy at Janney Montgomery Scott
FMS Fresenius Medical
$35.40 /

-2.24 (-5.95%)

03/05/20 Berenberg
Fresenius Medical price target lowered to EUR 89.70 from EUR 89.95 at Berenberg
01/21/20 Jefferies
Fresenius Medical upgraded to Buy from Hold at Jefferies
12/06/19 Morgan Stanley
Fresenius Medical downgraded to Underweight from Equal Weight at Morgan Stanley
10/23/19 Redburn
Redburn downgrades Fresenius Medical to Neutral on growth concerns
GRTS Gritstone Oncology
$6.64 /

-0.39 (-5.55%)

07/26/19
Fly Intel: Top five analyst initiations
07/25/19 Baird
Gritstone Oncology initiated with an Outperform at Baird
03/27/19 Berenberg
Gritstone Oncology initiated with a Buy at Berenberg
03/14/19 Raymond James
Gritstone Oncology initiated with an Outperform at Raymond James
HRC Hill-Rom
$89.24 /

-0.89 (-0.99%)

12/17/19 Morgan Stanley
Hill-Rom upgraded to Overweight on accelerating momentum at Morgan Stanley
12/17/19 Morgan Stanley
Hill-Rom upgraded to Overweight from Equal Weight at Morgan Stanley
06/27/19 Raymond James
Hill-Rom's DoD contract win a 'nice development,' says Raymond James
HUM Humana
$328.50 /

-20.52 (-5.88%)

01/23/20 UBS
Humana price target raised to $406 from $321 at UBS
01/08/20 Credit Suisse
Humana price target raised to $400 from $378 at Credit Suisse
IMMU Immunomedics
$13.38 /

-1.9 (-12.43%)

02/24/20 Jefferies
Epizyme, Blueprint among cancer companies that fit M&A criteria, says Jefferies
01/02/20 Guggenheim
Incyte downgraded to Neutral after strong 2019 at Guggenheim
12/27/19 H.C. Wainwright
Immunomedics price target raised to $31 from $26 at H.C. Wainwright
12/20/19 BofA
Immunomedics initiated with a Buy at BofA/Merrill
IRWD Ironwood
$10.49 /

-0.96 (-8.38%)

08/05/19 Credit Suisse
Ironwood assumed with a Neutral at Credit Suisse
07/10/19 Credit Suisse
Ironwood assumed with a Neutral at Credit Suisse
03/27/19 Morgan Stanley
Morgan Stanley upgrades Ironwood to Equal Weight on more stable Linzess growth
03/27/19 Morgan Stanley
Ironwood upgraded to Equal Weight from Underweight at Morgan Stanley
ITGR Integer
$79.28 /

-4.07 (-4.88%)

06/05/19 Argus
Integer price target lowered to $90 from $103 at Argus
JAZZ Jazz Pharmaceuticals
$108.33 /

-4.42 (-3.92%)

02/26/20 RBC Capital
Jazz Pharmaceuticals price target lowered to $164 from $184 at RBC Capital
02/26/20 Oppenheimer
Jazz Pharmaceuticals price target lowered to $154 from $183 at Oppenheimer
02/26/20 Cowen
Jazz Pharmaceuticals lowered his price target to $165 from $200 at Cowen
02/26/20 Piper Sandler
Jazz Pharmaceuticals price target lowered to $129 from $142 at Piper Sandler
JNJ Johnson & Johnson
$131.65 /

-10.05 (-7.09%)

03/11/20 H.C. Wainwright
H.C. Wainwright reiterates Buy on Genmab following J&J drug announcement
03/06/20 Credit Suisse
Johnson & Johnson price target lowered to $159 from $170 at Credit Suisse
03/04/20 Citi
Johnson & Johnson initiated with a Buy at Citi
ZIOP Ziopharm
$2.53 /

-0.24 (-8.68%)

03/04/20
Fly Intel: Top five analyst initiations
03/04/20 Cantor Fitzgerald
Ziopharm initiated with Overweight, $6 price target at Cantor Fitzgerald
03/03/20 Cantor Fitzgerald
Ziopharm initiated with an Overweight at Cantor Fitzgerald
08/23/19
Fly Intel: Top five analyst initiations
VNDA Vanda Pharmaceuticals
$10.60 /

-0.2 (-1.85%)

03/12/20 Citi
Vanda Pharmaceuticals upgraded to Buy from Neutral at Citi
02/27/20 Oppenheimer
Vanda Pharmaceuticals price target lowered to $12 from $18 at Oppenheimer
02/26/20 JMP Securities
Vanda Pharmaceuticals price target lowered to $25 from $52 at JMP Securities
11/07/19 Citi
Citi downgrades Vanda to Neutral after 'excessive' post-earnings rally
QGEN Qiagen
$41.10 /

-0.33 (-0.80%)

03/04/20 Stifel
Qiagen deal a positive for Thermo Fisher, says Stifel
03/04/20 Berenberg
Qiagen downgraded to Hold from Buy at Berenberg
03/03/20 Piper Sandler
Danaher unlikely to make competing bid for Qiagen, says Piper Sandler
02/05/20 Piper Sandler
Qiagen price target raised to $36 from $29 at Piper Sandler
MRNA Moderna
$23.61 /

+1.27 (+5.68%)

03/05/20
Fly Intel: Top five analyst downgrades
03/05/20 BofA
Moderna downgraded to Neutral from Buy at BofA
03/05/20 BofA
Moderna downgraded to Neutral from Buy at BofA
03/04/20 Piper Sandler
Moderna's Manufacturing & Digital Day showcases its mRNA advantages, says Piper
MTD Mettler-Toledo
$661.68 /

-35 (-5.02%)

02/07/20 UBS
Mettler-Toledo upgraded to Neutral from Sell at UBS
01/07/20 Wells Fargo
Mettler-Toledo initiated with an Equal Weight at Wells Fargo
01/06/20 Citi
Mettler-Toledo initiated with a Neutral at Citi
01/02/20 Evercore ISI
Mettler-Toledo upgraded to In Line from Underperform at Evercore ISI
MTEM Molecular Templates
$13.20 /

-1.48 (-10.08%)

02/27/20 Barclays
Molecular Templates initiated with an Overweight at Barclays
02/27/20 Barclays
Molecular Templates initiated with an Overweight at Barclays
04/29/19 UBS
Molecular Templates initiated with a Buy at UBS
NTRA Natera
$31.00 /

+0.07 (+0.23%)

02/27/20 Piper Sandler
Natera price target raised to $49 from $45 at Piper Sandler
12/19/19 Craig-Hallum
Natera kidney test to be covered under Medicare in February, says Craig-Hallum
12/19/19 Piper Sandler
CareDx should be bought on weakness from Natera coverage, says Piper
11/11/19 Canaccord
Natera results solid, remains a top pick at Canaccord
PODD Insulet
$172.13 /

-8.29 (-4.59%)

03/04/20 Citi
Insulet initiated with a Buy at Citi
03/02/20 Piper Sandler
Insulet should be bought on selloff from trial delay, says Piper Sandler
02/26/20 Cowen
Insulet weakness a buying opportunity, says Cowen
02/26/20 Raymond James
Insulet price target lowered to $205 from $213 at Raymond James
PTCT PTC Therapeutics
$47.07 /

-4.23 (-8.25%)

03/03/20 Cantor Fitzgerald
PTC Therapeutics price target raised to $86 from $81 at Cantor Fitzgerald
02/20/20 RBC Capital
PTC Therapeutics downgraded to Sector Perform from Outperform at RBC Capital
02/20/20 Citi
PTC Therapeutics downgraded to Neutral from Buy at Citi
02/20/20 RBC Capital
PTC Therapeutics downgraded to Sector Perform from Outperform at RBC Capital
Conference/Events
Barclays to hold a conference » 04:55
03/11/20
03/11
04:55
03/11/20
04:55
ABC

AmerisourceBergen

$86.11 /

+2.8 (+3.36%)

, AMAG

Amag Pharmaceuticals

$7.26 /

+0.05 (+0.69%)

, AZN

AstraZeneca

$46.89 /

+1.62 (+3.58%)

, AVNS

Avanos

$32.11 /

+0.31 (+0.97%)

, BDX

Becton Dickinson

$237.32 /

+6.55 (+2.84%)

, BIO

Bio-Rad

$367.05 /

+15 (+4.26%)

, CAH

Cardinal Health

$49.71 /

+1.72 (+3.58%)

, CLVS

Clovis

$6.27 /

+0.01 (+0.16%)

, COO

Cooper Companies

$333.99 /

+16.38 (+5.16%)

, CVS

CVS Health

$62.62 /

+1.24 (+2.02%)

, DGX

Quest Diagnostics

$106.40 /

-3.43 (-3.12%)

, EHTH

eHealth

$133.94 /

+3.21 (+2.46%)

, EXEL

Exelixis

$18.41 /

+0.66 (+3.72%)

, FATE

Fate Therapeutics

$25.99 /

+1 (+4.00%)

, FLDM

Fluidigm

$2.89 /

+0.16 (+5.86%)

, FMS

Fresenius Medical

$37.64 /

+0.28 (+0.75%)

, GRTS

Gritstone Oncology

$7.03 /

+0.02 (+0.29%)

, HRC

Hill-Rom

$90.13 /

+1.34 (+1.51%)

, HUM

Humana

$349.02 /

+11.84 (+3.51%)

, IMMU

Immunomedics

$15.28 /

+0.21 (+1.39%)

, IRWD

Ironwood

$11.45 /

+0.14 (+1.24%)

, ITGR

Integer

$83.35 /

+3.1 (+3.86%)

, JAZZ

Jazz Pharmaceuticals

$112.75 /

+2.15 (+1.94%)

, JNJ

Johnson & Johnson

$141.70 /

+5.4 (+3.96%)

, ZIOP

Ziopharm

$2.77 /

-0.06 (-2.12%)

, VNDA

Vanda Pharmaceuticals

$10.80 /

+0.9 (+9.09%)

, QGEN

Qiagen

$41.43 /

+0.075 (+0.18%)

, MRNA

Moderna

$22.34 /

-1.95 (-8.03%)

, MTD

Mettler-Toledo

$696.68 /

+25.36 (+3.78%)

, MTEM

Molecular Templates

$14.68 /

-1.09 (-6.91%)

, NTRA

Natera

$30.93 /

-2.43 (-7.28%)

, PODD

Insulet

$180.42 /

+7.3 (+4.22%)

, PTCT

PTC Therapeutics

$51.35 /

+0.14 (+0.27%)

Global Healthcare…

Global Healthcare Conference 2020 will be held in Miami on March 10-12.

ShowHide Related Items >><<
ABC AmerisourceBergen
$86.11 /

+2.8 (+3.36%)

02/07/20 Baird
AmerisourceBergen upgraded to Outperform at Baird
02/07/20 Baird
AmerisourceBergen upgraded to Outperform from Neutral at Baird
01/28/20 Cleveland Research
AmerisourceBergen appears to be gaining share, says Cleveland Research
10/16/19 Jefferies
Drug distributor settlement would make stocks 'ownable again,' says Jefferies
AMAG Amag Pharmaceuticals
$7.26 /

+0.05 (+0.69%)

03/04/20 Piper Sandler
Amag Pharmaceuticals price target lowered to $7 from $9 at Piper Sandler
03/03/20 H.C. Wainwright
Amag Pharmaceuticals price target lowered to $12 from $16 at H.C. Wainwright
01/09/20 Piper Sandler
Amag business still facing 'significant challenges,' says Piper Sandler
11/04/19 Barclays
Amag Pharmaceuticals price target lowered to $14 from $16 at Barclays
AZN AstraZeneca
$46.89 /

+1.62 (+3.58%)

02/28/20 Cowen
AstaZeneca pipeline leads to best European idea, says Cowen
01/27/20 William Blair
PhaseBio could see increase to PB2452 addressable market, says William Blair
01/22/20 Liberum
Sanofi downgraded to Hold from Buy at Liberum (earlier)
01/22/20 Oppenheimer
Amarin price target raised to $13 from $8 at Oppenheimer
AVNS Avanos
$32.11 /

+0.31 (+0.97%)

12/30/19 Stifel
Avanos makes 'welcome addition' with 'highly experienced' CFO, says Stifel
11/06/19 Stifel
Avanos downgraded to Hold from Buy at Stifel
11/06/19 Stifel
Avanos downgraded to Hold from Buy at Stifel
11/06/19 Raymond James
Avanos shares could be range-bound over next six months, says Raymond James
BDX Becton Dickinson
$237.32 /

+6.55 (+2.84%)

03/04/20 Citi
Becton Dickinson initiated with a Neutral at Citi
03/02/20 Wells Fargo
Baxter, J&J best positioned to weather coronavirus spread, says Wells Fargo
02/07/20
Fly Intel: Top five analyst downgrades
02/07/20 Raymond James
Becton Dickinson downgraded at Raymond James given pump overhang
BIO Bio-Rad
$367.05 /

+15 (+4.26%)

03/03/20 Citi
Bio-Rad margin expansion story in early innings, says Citi
01/07/20 Wells Fargo
Wells Fargo initiates Life Science Tools, Services, Diagnostics Sector
01/07/20 Wells Fargo
Bio-Rad initiated with an Overweight at Wells Fargo
01/06/20 Citi
Citi calls Bio-Rad, Thermo Fisher top picks in Tools industry
CAH Cardinal Health
$49.71 /

+1.72 (+3.58%)

02/12/20 Morgan Stanley
Cardinal Health upgraded to Equal Weight from Underweight at Morgan Stanley
02/07/20 Baird
Cardinal Health upgraded to Outperform at Baird
02/07/20 Mizuho
Cardinal Health price target raised to $58 from $52 at Mizuho
02/07/20 Baird
Cardinal Health upgraded to Outperform from Neutral at Baird
CLVS Clovis
$6.27 /

+0.01 (+0.16%)

02/25/20
Fly Intel: Top five analyst initiations
02/25/20 RBC Capital
Clovis initiated with an Outperform at RBC Capital
01/08/20 H.C. Wainwright
Clovis price target lowered to $27 from $36 at H.C. Wainwright
01/07/20 Piper Sandler
Clovis modestly extends cash runway with debt deal, says Piper Sandler
COO Cooper Companies
$333.99 /

+16.38 (+5.16%)

03/06/20 Baird
Cooper Companies price target raised to $357 from $345 at Baird
03/06/20 Piper Sandler
Cooper Companies price target raised to $351 from $344 at Piper Sandler
03/04/20 Citi
Cooper Companies initiated with a Neutral at Citi
CVS CVS Health
$62.62 /

+1.24 (+2.02%)

02/20/20 Stephens
Stephens watching near-term MCO stock reactions after Bloomberg's 'rough' debate
02/18/20 Deutsche Bank
Deutsche raises price targets in Managed Care on fading political risks
02/10/20 Cowen
CVS upside to guidance seen, says Cowen
01/21/20 Cantor Fitzgerald
CVS, Cigna and Centene a buy on any block grant selloff, says Cantor
DGX Quest Diagnostics
$106.40 /

-3.43 (-3.12%)

03/06/20 Jefferies
COVID-19 tests unlikely to move needle for Quest or LabCorp, says Jefferies
03/05/20 JPMorgan
Quest Diagnostics' COVID-19 testing to be small benefit for 2020, says JPMorgan
02/10/20 Mizuho
Quest Diagnostics price target raised to $122 from $116 at Mizuho
01/30/20 Piper Sandler
Quest Diagnostics price target raised to $107 from $102 at Piper Sandler
EHTH eHealth
$133.94 /

+3.21 (+2.46%)

02/24/20 Credit Suisse
eHealth price target raised to $179 from $145 at Credit Suisse
02/21/20 SunTrust
eHealth price target raised to $250 from $200 at SunTrust
02/21/20 Craig-Hallum
eHealth price target raised to $200 from $150 at Craig-Hallum
02/21/20 RBC Capital
eHealth price target raised to $166 from $132 at RBC Capital
EXEL Exelixis
$18.41 /

+0.66 (+3.72%)

03/04/20 Barclays
Barclays starts small, mid cap Biotechnology sector with Positive view
03/04/20 Barclays
Exelixis initiated with an Overweight at Barclays
02/27/20 Piper Sandler
Exelixis price target lowered to $23 from $35 at Piper Sandler
02/11/20 Piper Sandler
Exelixis data 'impressive,' support accelerated approval, says Piper Sandler
FATE Fate Therapeutics
$25.99 /

+1 (+4.00%)

03/04/20 Citi
Fate Therapeutics price target raised to $41 from $26 at Citi
03/04/20 Barclays
Fate Therapeutics initiated with an Overweight at Barclays
03/03/20 BMO Capital
Fate Therapeutics price target raised to $28 from $22 at BMO Capital
FLDM Fluidigm
$2.89 /

+0.16 (+5.86%)

02/11/20 Piper Sandler
Fluidigm price target lowered to $9 from $14 at Piper Sandler
01/14/20 Piper Sandler
Piper Sandler reiterates Overweight on Fluidigm after Q4 results, guidance
11/06/19 Janney Montgomery Scott
Fluidigm downgraded to Neutral after Q3 miss at Janney Montgomery Scott
11/06/19 Janney Montgomery Scott
Fluidigm downgraded to Neutral from Buy at Janney Montgomery Scott
FMS Fresenius Medical
$37.64 /

+0.28 (+0.75%)

03/05/20 Berenberg
Fresenius Medical price target lowered to EUR 89.70 from EUR 89.95 at Berenberg
01/21/20 Jefferies
Fresenius Medical upgraded to Buy from Hold at Jefferies
12/06/19 Morgan Stanley
Fresenius Medical downgraded to Underweight from Equal Weight at Morgan Stanley
10/23/19 Redburn
Redburn downgrades Fresenius Medical to Neutral on growth concerns
GRTS Gritstone Oncology
$7.03 /

+0.02 (+0.29%)

07/26/19
Fly Intel: Top five analyst initiations
07/25/19 Baird
Gritstone Oncology initiated with an Outperform at Baird
03/27/19 Berenberg
Gritstone Oncology initiated with a Buy at Berenberg
03/14/19 Raymond James
Gritstone Oncology initiated with an Outperform at Raymond James
HRC Hill-Rom
$90.13 /

+1.34 (+1.51%)

12/17/19 Morgan Stanley
Hill-Rom upgraded to Overweight on accelerating momentum at Morgan Stanley
12/17/19 Morgan Stanley
Hill-Rom upgraded to Overweight from Equal Weight at Morgan Stanley
06/27/19 Raymond James
Hill-Rom's DoD contract win a 'nice development,' says Raymond James
HUM Humana
$349.02 /

+11.84 (+3.51%)

01/23/20 UBS
Humana price target raised to $406 from $321 at UBS
01/08/20 Credit Suisse
Humana price target raised to $400 from $378 at Credit Suisse
IMMU Immunomedics
$15.28 /

+0.21 (+1.39%)

02/24/20 Jefferies
Epizyme, Blueprint among cancer companies that fit M&A criteria, says Jefferies
01/02/20 Guggenheim
Incyte downgraded to Neutral after strong 2019 at Guggenheim
12/27/19 H.C. Wainwright
Immunomedics price target raised to $31 from $26 at H.C. Wainwright
12/20/19 BofA
Immunomedics initiated with a Buy at BofA/Merrill
IRWD Ironwood
$11.45 /

+0.14 (+1.24%)

08/05/19 Credit Suisse
Ironwood assumed with a Neutral at Credit Suisse
07/10/19 Credit Suisse
Ironwood assumed with a Neutral at Credit Suisse
03/27/19 Morgan Stanley
Morgan Stanley upgrades Ironwood to Equal Weight on more stable Linzess growth
03/27/19 Morgan Stanley
Ironwood upgraded to Equal Weight from Underweight at Morgan Stanley
ITGR Integer
$83.35 /

+3.1 (+3.86%)

06/05/19 Argus
Integer price target lowered to $90 from $103 at Argus
JAZZ Jazz Pharmaceuticals
$112.75 /

+2.15 (+1.94%)

02/26/20 RBC Capital
Jazz Pharmaceuticals price target lowered to $164 from $184 at RBC Capital
02/26/20 Oppenheimer
Jazz Pharmaceuticals price target lowered to $154 from $183 at Oppenheimer
02/26/20 Cowen
Jazz Pharmaceuticals lowered his price target to $165 from $200 at Cowen
02/26/20 Piper Sandler
Jazz Pharmaceuticals price target lowered to $129 from $142 at Piper Sandler
JNJ Johnson & Johnson
$141.70 /

+5.4 (+3.96%)

03/06/20 Credit Suisse
Johnson & Johnson price target lowered to $159 from $170 at Credit Suisse
03/04/20 Citi
Johnson & Johnson initiated with a Buy at Citi
01/27/20 Credit Suisse
Johnson & Johnson price target raised to $170 from $163 at Credit Suisse
ZIOP Ziopharm
$2.77 /

-0.06 (-2.12%)

03/04/20
Fly Intel: Top five analyst initiations
03/04/20 Cantor Fitzgerald
Ziopharm initiated with Overweight, $6 price target at Cantor Fitzgerald
03/03/20 Cantor Fitzgerald
Ziopharm initiated with an Overweight at Cantor Fitzgerald
08/23/19
Fly Intel: Top five analyst initiations
VNDA Vanda Pharmaceuticals
$10.80 /

+0.9 (+9.09%)

02/27/20 Oppenheimer
Vanda Pharmaceuticals price target lowered to $12 from $18 at Oppenheimer
02/26/20 JMP Securities
Vanda Pharmaceuticals price target lowered to $25 from $52 at JMP Securities
11/07/19 Citi
Citi downgrades Vanda to Neutral after 'excessive' post-earnings rally
11/07/19 Citi
Vanda Pharmaceuticals downgraded to Neutral from Buy at Citi
QGEN Qiagen
$41.43 /

+0.075 (+0.18%)

03/04/20 Stifel
Qiagen deal a positive for Thermo Fisher, says Stifel
03/04/20 Berenberg
Qiagen downgraded to Hold from Buy at Berenberg
03/03/20 Piper Sandler
Danaher unlikely to make competing bid for Qiagen, says Piper Sandler
02/05/20 Piper Sandler
Qiagen price target raised to $36 from $29 at Piper Sandler
MRNA Moderna
$22.34 /

-1.95 (-8.03%)

03/05/20
Fly Intel: Top five analyst downgrades
03/05/20 BofA
Moderna downgraded to Neutral from Buy at BofA
03/05/20 BofA
Moderna downgraded to Neutral from Buy at BofA
03/04/20 Piper Sandler
Moderna's Manufacturing & Digital Day showcases its mRNA advantages, says Piper
MTD Mettler-Toledo
$696.68 /

+25.36 (+3.78%)

02/07/20 UBS
Mettler-Toledo upgraded to Neutral from Sell at UBS
01/07/20 Wells Fargo
Mettler-Toledo initiated with an Equal Weight at Wells Fargo
01/06/20 Citi
Mettler-Toledo initiated with a Neutral at Citi
01/02/20 Evercore ISI
Mettler-Toledo upgraded to In Line from Underperform at Evercore ISI
MTEM Molecular Templates
$14.68 /

-1.09 (-6.91%)

02/27/20 Barclays
Molecular Templates initiated with an Overweight at Barclays
02/27/20 Barclays
Molecular Templates initiated with an Overweight at Barclays
04/29/19 UBS
Molecular Templates initiated with a Buy at UBS
NTRA Natera
$30.93 /

-2.43 (-7.28%)

02/27/20 Piper Sandler
Natera price target raised to $49 from $45 at Piper Sandler
12/19/19 Craig-Hallum
Natera kidney test to be covered under Medicare in February, says Craig-Hallum
12/19/19 Piper Sandler
CareDx should be bought on weakness from Natera coverage, says Piper
11/11/19 Canaccord
Natera results solid, remains a top pick at Canaccord
PODD Insulet
$180.42 /

+7.3 (+4.22%)

03/04/20 Citi
Insulet initiated with a Buy at Citi
03/02/20 Piper Sandler
Insulet should be bought on selloff from trial delay, says Piper Sandler
02/26/20 Cowen
Insulet weakness a buying opportunity, says Cowen
02/26/20 Raymond James
Insulet price target lowered to $205 from $213 at Raymond James
PTCT PTC Therapeutics
$51.35 /

+0.14 (+0.27%)

03/03/20 Cantor Fitzgerald
PTC Therapeutics price target raised to $86 from $81 at Cantor Fitzgerald
02/20/20 RBC Capital
PTC Therapeutics downgraded to Sector Perform from Outperform at RBC Capital
02/20/20 Citi
PTC Therapeutics downgraded to Neutral from Buy at Citi
02/20/20 RBC Capital
PTC Therapeutics downgraded to Sector Perform from Outperform at RBC Capital
Conference/Events
Barclays to hold a conference » 08:27
03/10/20
03/10
08:27
03/10/20
08:27
ABC

AmerisourceBergen

$83.31 /

-2.49 (-2.90%)

, AMAG

Amag Pharmaceuticals

$7.21 /

-0.47 (-6.12%)

, AZN

AstraZeneca

$45.27 /

-2.25 (-4.73%)

, AVNS

Avanos

$31.80 /

-0.71 (-2.18%)

, BDX

Becton Dickinson

$232.60 /

-4.81 (-2.03%)

, BIO

Bio-Rad

$352.05 /

-23.16 (-6.17%)

, CAH

Cardinal Health

$47.99 /

-3.22 (-6.29%)

, CLVS

Clovis

$6.26 /

-1.585 (-20.22%)

, COO

Cooper Companies

$317.61 /

-15.52 (-4.66%)

, CVS

CVS Health

$61.38 /

-2.76 (-4.30%)

, DGX

Quest Diagnostics

$109.83 /

-2.17 (-1.94%)

, EHTH

eHealth

$130.56 /

-3.85 (-2.86%)

, EXEL

Exelixis

$17.75 /

-0.88 (-4.72%)

, FATE

Fate Therapeutics

$24.99 /

-4.35 (-14.83%)

, FLDM

Fluidigm

$2.73 /

-0.24 (-8.08%)

, FMS

Fresenius Medical

$37.36 /

-1.82 (-4.65%)

, GRTS

Gritstone Oncology

$7.01 /

-0.84 (-10.70%)

, HRC

Hill-Rom

$88.79 /

-7.16 (-7.46%)

, HUM

Humana

$337.18 /

-29.73 (-8.10%)

, IMMU

Immunomedics

$15.07 /

-1.35 (-8.22%)

, IRWD

Ironwood

$11.31 /

-0.93 (-7.60%)

, ITGR

Integer

$80.25 /

-4.87 (-5.72%)

, JAZZ

Jazz Pharmaceuticals

$110.60 /

-9.17 (-7.66%)

, JNJ

Johnson & Johnson

$136.30 /

-5.83 (-4.10%)

, ZIOP

Ziopharm

$2.83 /

-0.435 (-13.34%)

, VNDA

Vanda Pharmaceuticals

$9.90 /

-0.62 (-5.89%)

, QGEN

Qiagen

$41.36 /

-0.225 (-0.54%)

, MRNA

Moderna

$24.29 /

-5.29 (-17.88%)

, MTD

Mettler-Toledo

$671.32 /

-43.68 (-6.11%)

, MTEM

Molecular Templates

$15.77 /

-1.6 (-9.21%)

, NTRA

Natera

$33.36 /

-4.97 (-12.97%)

, PODD

Insulet

$173.12 /

-6.39 (-3.56%)

, PTCT

PTC Therapeutics

$51.21 /

-3.8 (-6.91%)

Global Healthcare…

Global Healthcare Conference 2020 will be held in Miami on March 10-12.

ShowHide Related Items >><<
ABC AmerisourceBergen
$83.31 /

-2.49 (-2.90%)

02/07/20 Baird
AmerisourceBergen upgraded to Outperform at Baird
02/07/20 Baird
AmerisourceBergen upgraded to Outperform from Neutral at Baird
01/28/20 Cleveland Research
AmerisourceBergen appears to be gaining share, says Cleveland Research
10/16/19 Jefferies
Drug distributor settlement would make stocks 'ownable again,' says Jefferies
AMAG Amag Pharmaceuticals
$7.21 /

-0.47 (-6.12%)

03/04/20 Piper Sandler
Amag Pharmaceuticals price target lowered to $7 from $9 at Piper Sandler
03/03/20 H.C. Wainwright
Amag Pharmaceuticals price target lowered to $12 from $16 at H.C. Wainwright
01/09/20 Piper Sandler
Amag business still facing 'significant challenges,' says Piper Sandler
11/04/19 Barclays
Amag Pharmaceuticals price target lowered to $14 from $16 at Barclays
AZN AstraZeneca
$45.27 /

-2.25 (-4.73%)

02/28/20 Cowen
AstaZeneca pipeline leads to best European idea, says Cowen
01/27/20 William Blair
PhaseBio could see increase to PB2452 addressable market, says William Blair
01/22/20 Liberum
Sanofi downgraded to Hold from Buy at Liberum (earlier)
01/22/20 Oppenheimer
Amarin price target raised to $13 from $8 at Oppenheimer
AVNS Avanos
$31.80 /

-0.71 (-2.18%)

12/30/19 Stifel
Avanos makes 'welcome addition' with 'highly experienced' CFO, says Stifel
11/06/19 Stifel
Avanos downgraded to Hold from Buy at Stifel
11/06/19 Stifel
Avanos downgraded to Hold from Buy at Stifel
11/06/19 Raymond James
Avanos shares could be range-bound over next six months, says Raymond James
BDX Becton Dickinson
$232.60 /

-4.81 (-2.03%)

03/04/20 Citi
Becton Dickinson initiated with a Neutral at Citi
03/02/20 Wells Fargo
Baxter, J&J best positioned to weather coronavirus spread, says Wells Fargo
02/07/20
Fly Intel: Top five analyst downgrades
02/07/20 Raymond James
Becton Dickinson downgraded at Raymond James given pump overhang
BIO Bio-Rad
$352.05 /

-23.16 (-6.17%)

03/03/20 Citi
Bio-Rad margin expansion story in early innings, says Citi
01/07/20 Wells Fargo
Wells Fargo initiates Life Science Tools, Services, Diagnostics Sector
01/07/20 Wells Fargo
Bio-Rad initiated with an Overweight at Wells Fargo
01/06/20 Citi
Citi calls Bio-Rad, Thermo Fisher top picks in Tools industry
CAH Cardinal Health
$47.99 /

-3.22 (-6.29%)

02/12/20 Morgan Stanley
Cardinal Health upgraded to Equal Weight from Underweight at Morgan Stanley
02/07/20 Baird
Cardinal Health upgraded to Outperform at Baird
02/07/20 Mizuho
Cardinal Health price target raised to $58 from $52 at Mizuho
02/07/20 Baird
Cardinal Health upgraded to Outperform from Neutral at Baird
CLVS Clovis
$6.26 /

-1.585 (-20.22%)

02/25/20
Fly Intel: Top five analyst initiations
02/25/20 RBC Capital
Clovis initiated with an Outperform at RBC Capital
01/08/20 H.C. Wainwright
Clovis price target lowered to $27 from $36 at H.C. Wainwright
01/07/20 Piper Sandler
Clovis modestly extends cash runway with debt deal, says Piper Sandler
COO Cooper Companies
$317.61 /

-15.52 (-4.66%)

03/06/20 Baird
Cooper Companies price target raised to $357 from $345 at Baird
03/06/20 Piper Sandler
Cooper Companies price target raised to $351 from $344 at Piper Sandler
03/04/20 Citi
Cooper Companies initiated with a Neutral at Citi
CVS CVS Health
$61.38 /

-2.76 (-4.30%)

02/20/20 Stephens
Stephens watching near-term MCO stock reactions after Bloomberg's 'rough' debate
02/18/20 Deutsche Bank
Deutsche raises price targets in Managed Care on fading political risks
02/10/20 Cowen
CVS upside to guidance seen, says Cowen
01/21/20 Cantor Fitzgerald
CVS, Cigna and Centene a buy on any block grant selloff, says Cantor
DGX Quest Diagnostics
$109.83 /

-2.17 (-1.94%)

03/06/20 Jefferies
COVID-19 tests unlikely to move needle for Quest or LabCorp, says Jefferies
03/05/20 JPMorgan
Quest Diagnostics' COVID-19 testing to be small benefit for 2020, says JPMorgan
02/10/20 Mizuho
Quest Diagnostics price target raised to $122 from $116 at Mizuho
01/30/20 Piper Sandler
Quest Diagnostics price target raised to $107 from $102 at Piper Sandler
EHTH eHealth
$130.56 /

-3.85 (-2.86%)

02/24/20 Credit Suisse
eHealth price target raised to $179 from $145 at Credit Suisse
02/21/20 SunTrust
eHealth price target raised to $250 from $200 at SunTrust
02/21/20 Craig-Hallum
eHealth price target raised to $200 from $150 at Craig-Hallum
02/21/20 RBC Capital
eHealth price target raised to $166 from $132 at RBC Capital
EXEL Exelixis
$17.75 /

-0.88 (-4.72%)

03/04/20 Barclays
Barclays starts small, mid cap Biotechnology sector with Positive view
03/04/20 Barclays
Exelixis initiated with an Overweight at Barclays
02/27/20 Piper Sandler
Exelixis price target lowered to $23 from $35 at Piper Sandler
02/11/20 Piper Sandler
Exelixis data 'impressive,' support accelerated approval, says Piper Sandler
FATE Fate Therapeutics
$24.99 /

-4.35 (-14.83%)

03/04/20 Citi
Fate Therapeutics price target raised to $41 from $26 at Citi
03/04/20 Barclays
Fate Therapeutics initiated with an Overweight at Barclays
03/03/20 BMO Capital
Fate Therapeutics price target raised to $28 from $22 at BMO Capital
FLDM Fluidigm
$2.73 /

-0.24 (-8.08%)

02/11/20 Piper Sandler
Fluidigm price target lowered to $9 from $14 at Piper Sandler
01/14/20 Piper Sandler
Piper Sandler reiterates Overweight on Fluidigm after Q4 results, guidance
11/06/19 Janney Montgomery Scott
Fluidigm downgraded to Neutral after Q3 miss at Janney Montgomery Scott
11/06/19 Janney Montgomery Scott
Fluidigm downgraded to Neutral from Buy at Janney Montgomery Scott
FMS Fresenius Medical
$37.36 /

-1.82 (-4.65%)

03/05/20 Berenberg
Fresenius Medical price target lowered to EUR 89.70 from EUR 89.95 at Berenberg
01/21/20 Jefferies
Fresenius Medical upgraded to Buy from Hold at Jefferies
12/06/19 Morgan Stanley
Fresenius Medical downgraded to Underweight from Equal Weight at Morgan Stanley
10/23/19 Redburn
Redburn downgrades Fresenius Medical to Neutral on growth concerns
GRTS Gritstone Oncology
$7.01 /

-0.84 (-10.70%)

07/26/19
Fly Intel: Top five analyst initiations
07/25/19 Baird
Gritstone Oncology initiated with an Outperform at Baird
03/27/19 Berenberg
Gritstone Oncology initiated with a Buy at Berenberg
03/14/19 Raymond James
Gritstone Oncology initiated with an Outperform at Raymond James
HRC Hill-Rom
$88.79 /

-7.16 (-7.46%)

12/17/19 Morgan Stanley
Hill-Rom upgraded to Overweight on accelerating momentum at Morgan Stanley
12/17/19 Morgan Stanley
Hill-Rom upgraded to Overweight from Equal Weight at Morgan Stanley
06/27/19 Raymond James
Hill-Rom's DoD contract win a 'nice development,' says Raymond James
HUM Humana
$337.18 /

-29.73 (-8.10%)

01/23/20 UBS
Humana price target raised to $406 from $321 at UBS
01/08/20 Credit Suisse
Humana price target raised to $400 from $378 at Credit Suisse
IMMU Immunomedics
$15.07 /

-1.35 (-8.22%)

02/24/20 Jefferies
Epizyme, Blueprint among cancer companies that fit M&A criteria, says Jefferies
01/02/20 Guggenheim
Incyte downgraded to Neutral after strong 2019 at Guggenheim
12/27/19 H.C. Wainwright
Immunomedics price target raised to $31 from $26 at H.C. Wainwright
12/20/19 BofA
Immunomedics initiated with a Buy at BofA/Merrill
IRWD Ironwood
$11.31 /

-0.93 (-7.60%)

08/05/19 Credit Suisse
Ironwood assumed with a Neutral at Credit Suisse
07/10/19 Credit Suisse
Ironwood assumed with a Neutral at Credit Suisse
03/27/19 Morgan Stanley
Morgan Stanley upgrades Ironwood to Equal Weight on more stable Linzess growth
03/27/19 Morgan Stanley
Ironwood upgraded to Equal Weight from Underweight at Morgan Stanley
ITGR Integer
$80.25 /

-4.87 (-5.72%)

06/05/19 Argus
Integer price target lowered to $90 from $103 at Argus
JAZZ Jazz Pharmaceuticals
$110.60 /

-9.17 (-7.66%)

02/26/20 RBC Capital
Jazz Pharmaceuticals price target lowered to $164 from $184 at RBC Capital
02/26/20 Oppenheimer
Jazz Pharmaceuticals price target lowered to $154 from $183 at Oppenheimer
02/26/20 Cowen
Jazz Pharmaceuticals lowered his price target to $165 from $200 at Cowen
02/26/20 Piper Sandler
Jazz Pharmaceuticals price target lowered to $129 from $142 at Piper Sandler
JNJ Johnson & Johnson
$136.30 /

-5.83 (-4.10%)

03/06/20 Credit Suisse
Johnson & Johnson price target lowered to $159 from $170 at Credit Suisse
03/04/20 Citi
Johnson & Johnson initiated with a Buy at Citi
01/27/20 Credit Suisse
Johnson & Johnson price target raised to $170 from $163 at Credit Suisse
ZIOP Ziopharm
$2.83 /

-0.435 (-13.34%)

03/04/20
Fly Intel: Top five analyst initiations
03/04/20 Cantor Fitzgerald
Ziopharm initiated with Overweight, $6 price target at Cantor Fitzgerald
03/03/20 Cantor Fitzgerald
Ziopharm initiated with an Overweight at Cantor Fitzgerald
08/23/19
Fly Intel: Top five analyst initiations
VNDA Vanda Pharmaceuticals
$9.90 /

-0.62 (-5.89%)

02/27/20 Oppenheimer
Vanda Pharmaceuticals price target lowered to $12 from $18 at Oppenheimer
02/26/20 JMP Securities
Vanda Pharmaceuticals price target lowered to $25 from $52 at JMP Securities
11/07/19 Citi
Citi downgrades Vanda to Neutral after 'excessive' post-earnings rally
11/07/19 Citi
Vanda Pharmaceuticals downgraded to Neutral from Buy at Citi
QGEN Qiagen
$41.36 /

-0.225 (-0.54%)

03/04/20 Stifel
Qiagen deal a positive for Thermo Fisher, says Stifel
03/04/20 Berenberg
Qiagen downgraded to Hold from Buy at Berenberg
03/03/20 Piper Sandler
Danaher unlikely to make competing bid for Qiagen, says Piper Sandler
02/05/20 Piper Sandler
Qiagen price target raised to $36 from $29 at Piper Sandler
MRNA Moderna
$24.29 /

-5.29 (-17.88%)

03/05/20
Fly Intel: Top five analyst downgrades
03/05/20 BofA
Moderna downgraded to Neutral from Buy at BofA
03/05/20 BofA
Moderna downgraded to Neutral from Buy at BofA
03/04/20 Piper Sandler
Moderna's Manufacturing & Digital Day showcases its mRNA advantages, says Piper
MTD Mettler-Toledo
$671.32 /

-43.68 (-6.11%)

02/07/20 UBS
Mettler-Toledo upgraded to Neutral from Sell at UBS
01/07/20 Wells Fargo
Mettler-Toledo initiated with an Equal Weight at Wells Fargo
01/06/20 Citi
Mettler-Toledo initiated with a Neutral at Citi
01/02/20 Evercore ISI
Mettler-Toledo upgraded to In Line from Underperform at Evercore ISI
MTEM Molecular Templates
$15.77 /

-1.6 (-9.21%)

02/27/20 Barclays
Molecular Templates initiated with an Overweight at Barclays
02/27/20 Barclays
Molecular Templates initiated with an Overweight at Barclays
04/29/19 UBS
Molecular Templates initiated with a Buy at UBS
NTRA Natera
$33.36 /

-4.97 (-12.97%)

02/27/20 Piper Sandler
Natera price target raised to $49 from $45 at Piper Sandler
12/19/19 Craig-Hallum
Natera kidney test to be covered under Medicare in February, says Craig-Hallum
12/19/19 Piper Sandler
CareDx should be bought on weakness from Natera coverage, says Piper
11/11/19 Canaccord
Natera results solid, remains a top pick at Canaccord
PODD Insulet
$173.12 /

-6.39 (-3.56%)

03/04/20 Citi
Insulet initiated with a Buy at Citi
03/02/20 Piper Sandler
Insulet should be bought on selloff from trial delay, says Piper Sandler
02/26/20 Cowen
Insulet weakness a buying opportunity, says Cowen
02/26/20 Raymond James
Insulet price target lowered to $205 from $213 at Raymond James
PTCT PTC Therapeutics
$51.21 /

-3.8 (-6.91%)

03/03/20 Cantor Fitzgerald
PTC Therapeutics price target raised to $86 from $81 at Cantor Fitzgerald
02/20/20 RBC Capital
PTC Therapeutics downgraded to Sector Perform from Outperform at RBC Capital
02/20/20 Citi
PTC Therapeutics downgraded to Neutral from Buy at Citi
02/20/20 RBC Capital
PTC Therapeutics downgraded to Sector Perform from Outperform at RBC Capital
Earnings
Integer sees FY20 adj. EPS $5.10-$5.30, consensus $5.00 » 08:41
02/20/20
02/20
08:41
02/20/20
08:41
ITGR

Integer

$93.31 /

+2.68 (+2.96%)

Sees revenue…

Sees revenue $1.29B-$1.31B, consensus $1.29B.

ShowHide Related Items >><<
ITGR Integer
$93.31 /

+2.68 (+2.96%)

06/05/19 Argus
Integer price target lowered to $90 from $103 at Argus
Earnings
Integer reports Q4 adj. EPS $1.25, consensus $1.17 » 08:40
02/20/20
02/20
08:40
02/20/20
08:40
ITGR

Integer

$93.31 /

+2.68 (+2.96%)

Reports Q4 revenue $326M,…

Reports Q4 revenue $326M, consensus $321.33M. "Integer delivered strong earnings growth in 2019 as our Manufacturing Excellence strategic imperative is delivering operational and financial improvements. We exceeded our original 2019 adjusted profit guidance as we continue to deliver on our commitments to investors. We further strengthened our leadership team to enable us to accelerate the execution of our strategy and deliver for our customers," said Joseph Dziedzic, Integer's president and chief executive officer. "Yesterday we completed a bolt-on acquisition, which further strengthens our R&D capabilities and expands our global footprint into Israel, which is widely recognized as a leading innovation center. Our 2020 financial guidance delivers on our commitment to grow profit at least twice as fast as our sales growth rate, while making investments to execute our remaining strategic financial objective to deliver above market revenue growth."

ShowHide Related Items >><<
ITGR Integer
$93.31 /

+2.68 (+2.96%)

06/05/19 Argus
Integer price target lowered to $90 from $103 at Argus

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.